Skip to main content

Health condition · Clinically reviewed

Coronavirus and COVID-19, variants, antivirals, vaccination and Long COVID care.

Most infections are mild. A minority need antivirals or hospital care, and around 10 to 30 per cent of adults develop Long COVID. Here is how UK care fits together now.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, UKHSA, JCVI, WHO and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects the JN.1 and XEC-era vaccine programme, current antivirals and Long COVID care pathways.

Key facts

Coronavirus at a glance.

The essentials, in plain English. What it is, how it spreads, which variants matter and how UK care is organised.

  • What it is

    A family of enveloped RNA viruses. The main human pathogens are SARS-CoV-2 (COVID-19), SARS-CoV (2003), MERS-CoV and four endemic seasonal coronaviruses.

  • How it spreads

    Respiratory droplets and aerosols, with a smaller role for fomites. Incubation is typically 2 to 14 days and presymptomatic transmission is significant.

  • Seasonal strains

    229E, NL63, OC43 and HKU1 cause around 15 per cent of common colds each winter. See our common cold guide for detail.

  • Variants

    SARS-CoV-2 continues to evolve. Alpha, Beta, Gamma, Delta and Omicron were followed by BA.5, JN.1, KP.3 and XEC subvariants.

  • Spectrum of illness

    Most infections are mild or asymptomatic. A minority develop pneumonia, ARDS, thromboembolism or multisystem complications.

  • Long COVID

    Around 10 to 30 per cent of infected adults report symptoms beyond 12 weeks. Fatigue, cognitive change and dysautonomia are the most common.

Why this guide matters

A settled, evidence-based playbook.

COVID has moved from emergency into endemic care. What follows is what the UK evidence base and current guidance actually recommend today.

  • Vaccination still does the heavy lifting

    Autumn boosters targeted at circulating variants remain the most effective tool for reducing severe disease and hospital admission in eligible groups.

  • Antivirals need to be started early

    Nirmatrelvir-ritonavir and molnupiravir work best inside the first 5 days of symptoms. Eligibility is defined by NICE and applied by NHS COVID medicines pathways.

  • Long COVID deserves proper care

    Around 10 to 30 per cent of infected adults develop persistent symptoms. UK post-COVID services offer structured multidisciplinary rehabilitation.

How the diagnosis is made

From first symptoms to a clear plan.

The steps a UK GP, urgent care clinician or hospital team will typically follow, so you know what to expect.

  1. 01

    Assessing

    Symptoms and exposure history

    Onset, symptom pattern, household or workplace exposure, travel and vaccination status build the clinical picture.

  2. 02

    Assessing

    Risk stratification

    Age over 65, immunocompromise, pregnancy, obesity, diabetes, cardiovascular and chronic lung disease all raise the risk of severe illness.

  3. 03

    Assessing

    Lateral flow or PCR testing

    LFTs are widely available. PCR remains standard for hospital admission, immunocompromised patients and clinical trials.

  4. 04

    Confirming

    Bedside observations

    Oxygen saturations, respiratory rate, heart rate and temperature guide who needs escalation from community to hospital care.

  5. 05

    Confirming

    Bloods for moderate to severe

    FBC, CRP, D-dimer, ferritin, LDH, LFTs, troponin and BNP help stratify inflammation, coagulopathy and organ involvement.

  6. 06

    Following up

    Imaging when hypoxic

    Chest X-ray and, selectively, CT chest identify COVID pneumonia, pulmonary embolism and alternative diagnoses.

  7. 07

    Following up

    Long COVID assessment

    A structured symptom, functional and mental-health review, with referral to a UK post-COVID service when symptoms persist beyond 12 weeks.

Typical timeline: home test within hours, treatment decisions within days, Long COVID review at 12 weeks if symptoms persist.

Symptoms

What COVID actually looks like.

A spectrum, not a single illness. From asymptomatic infection through to lower respiratory disease, thrombosis, neurological and multisystem complications.

  • Upper respiratory symptoms

    Fever, cough, sore throat, rhinorrhoea, fatigue, myalgia and headache. Anosmia and ageusia were hallmark early strains, less common with Omicron.

  • Lower respiratory illness

    Dyspnoea, hypoxia and pneumonia. A small proportion progress to ARDS and respiratory failure needing hospital care.

  • Gastrointestinal features

    Diarrhoea, nausea and vomiting are recognised, sometimes without prominent respiratory symptoms.

  • Neurological involvement

    Headache, encephalitis, Guillain-Barré syndrome and stroke have been described, particularly during severe illness.

  • Dermatological signs

    Chilblain-like lesions (COVID toes), maculopapular rashes and urticaria have been reported across variants.

  • Thromboembolic disease

    DVT, pulmonary embolism, arterial events and microthrombi reflect the endothelial dysfunction seen in severe COVID.

  • Multisystem inflammatory syndromes

    MIS-C in children and MIS-A in adults present with fever, shock and multi-organ inflammation weeks after infection.

  • Red flag - severe hypoxia

    Rapidly rising respiratory rate, oxygen saturations below 92 per cent or new confusion need urgent hospital assessment.

Treatment

How COVID is treated in the UK.

Supportive care at home for most, targeted antivirals for high-risk groups within 5 days of symptoms, and dexamethasone, immunomodulators and respiratory support in hospital.

  • Supportive care at home

    Rest, fluids and paracetamol or ibuprofen for symptom control. Self-isolate per current UKHSA guidance and monitor for worsening breathlessness.

  • Nirmatrelvir-ritonavir (Paxlovid)

    Oral antiviral, 5-day course, started within 5 days of symptom onset for eligible high-risk patients per NICE criteria.

  • Molnupiravir (Lagevrio)

    Oral alternative for high-risk community patients when Paxlovid is unsuitable. Less effective, used selectively.

  • Remdesivir (Veklury)

    Intravenous antiviral for hospitalised patients with oxygen requirement or selected high-risk community cases via specialist pathways.

  • Dexamethasone

    Oral or IV corticosteroid, 6 mg for 10 days, in hospitalised patients needing oxygen. Practice-changing evidence from the RECOVERY trial.

  • Tocilizumab or baricitinib

    Immunomodulators added for severe or critical COVID with rising inflammation, per NHS commissioning criteria.

  • Oxygen and respiratory support

    Supplemental oxygen, high-flow nasal oxygen, CPAP or non-invasive ventilation, proning and, when needed, invasive ventilation or ECMO.

  • Vaccination and boosters

    mRNA vaccines (Comirnaty, Spikevax) and Novavax, with variant-updated autumn boosters for eligible groups defined by the JCVI.

Infection control and vulnerable patients

Hand hygiene, ventilation, masks and physical distancing remain useful adaptive tools when prevalence is high or around vulnerable contacts. Prophylactic monoclonal antibodies (such as Evusheld) have been withdrawn as variant escape reduced their efficacy. Long COVID care is delivered through UK post-COVID services and covers graded activity, pacing, POTS management, cognitive rehabilitation and mental-health support.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. COVID-19 rapid guideline: managing COVID-19 (NG191).

  • NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188).

  • UK Health Security Agency (UKHSA). COVID-19 guidance for the public and healthcare professionals.

  • JCVI. Advice on the COVID-19 vaccination programme.

  • WHO. Living guidance on clinical management of COVID-19.

Red flags

When COVID needs urgent attention.

Most infections can be managed at home. These are the situations that need same-day clinical review, hospital care or specialist follow-up.

  • Severe breathlessness or hypoxia

    Rising respiratory rate, oxygen saturations below 92 per cent or difficulty completing sentences needs same-day hospital assessment.

  • Chest pain or suspected PE

    Pleuritic chest pain, unilateral leg swelling or sudden breathlessness in a COVID patient raises concern for pulmonary embolism.

  • New confusion or reduced consciousness

    Delirium, drowsiness or focal neurology is a red flag for hypoxia, sepsis or a neurological complication.

  • Signs of sepsis

    High fever with rigors, mottled skin, low blood pressure or reduced urine output needs urgent hospital care.

  • MIS-C in children

    Persistent high fever, rash, red eyes, abdominal pain or shock 2 to 6 weeks after infection needs immediate paediatric review.

  • Vulnerable and unvaccinated

    Immunocompromised, transplant, chemotherapy or advanced organ disease patients should seek early clinical review with any COVID symptoms.

  • Persistent symptoms beyond 12 weeks

    Ongoing fatigue, breathlessness, brain fog or palpitations warrant a Long COVID assessment via the GP or specialist service.

  • New-onset diabetes or cardiac symptoms

    Post-COVID new type 1 diabetes, myocarditis or pericarditis have been described and should be actively investigated.

  • Pregnancy with COVID

    Pregnant patients face higher risk of severe disease and should be reviewed early via maternity and obstetric services.

Living with it

An endemic virus, managed with the right habits.

Four things that make the biggest difference. Vaccinate when eligible, test early if you are high-risk, pace recovery and escalate breathlessness or chest pain quickly.

A quiet reminder

Recovery from a viral illness is not linear.

Good days and bad days are the norm. Sustained rest and gradual, staged activity beat pushing through, especially where fatigue lingers.

  1. 01 Prevention

    Vaccinate on schedule

    Take the autumn booster if you are eligible. Vaccination remains the single most effective way to reduce severe disease and death.

  2. 02 Test

    Test early if you are high-risk

    If you are eligible for antivirals, a positive lateral flow within the first 5 days of symptoms unlocks treatment that works best when started early.

  3. 03 Pace

    Recover slowly, not heroically

    For Long COVID and post-viral fatigue, pacing and graded activity work better than pushing through. Rest is treatment.

  4. 04 Escalate

    Do not sit on breathlessness

    New or worsening breathlessness, chest pain or confusion should trigger a same-day clinical review, not a wait-and-see.

Frequently asked

Everything we get asked about coronavirus.

Quick answers on variants, antivirals, vaccination and Long COVID.

  • What is coronavirus?

    Coronaviruses are a family of enveloped RNA viruses. The most important human pathogens are SARS-CoV-2 (COVID-19), SARS-CoV (2003), MERS-CoV and four endemic seasonal coronaviruses (229E, NL63, OC43 and HKU1) that cause around 15 per cent of common colds each winter.

  • How is COVID-19 spread?

    Mainly through respiratory droplets and smaller aerosols, with a smaller role for surfaces (fomites). Incubation is typically 2 to 14 days, and presymptomatic and asymptomatic transmission is significant, which is why hand hygiene, ventilation and testing when symptomatic remain important.

  • Which variants matter now?

    SARS-CoV-2 continues to evolve. After Alpha, Beta, Gamma, Delta and Omicron, subvariants such as BA.5, JN.1, KP.3 and XEC have dominated. UK autumn boosters are updated to match the currently circulating strains on JCVI advice.

  • Who is eligible for COVID antivirals?

    NICE limits community antivirals to defined high-risk groups, including immunocompromised patients, some people aged over 70 and those with specific comorbidities. Nirmatrelvir-ritonavir (Paxlovid) is first-line where suitable, started within 5 days of symptom onset. Molnupiravir is an alternative in selected cases.

  • What is Long COVID?

    Long COVID, or post-COVID condition, describes symptoms that persist beyond 12 weeks and are not explained by another diagnosis. It affects roughly 10 to 30 per cent of infected adults. Fatigue, brain fog, breathlessness, palpitations, POTS, chronic pain and mood symptoms are the most common features.

  • How is Long COVID treated?

    Management is multidisciplinary and delivered through UK post-COVID services. It includes pacing and graded activity, breathing rehabilitation, POTS and dysautonomia care, cognitive rehabilitation and treatment of coexisting anxiety, depression and sleep problems. See our Long COVID rehab clinic guide for more.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.